Can low hemoglobin and MCHC contribute to fatigue?

Sub-optimal hemoglobin (Hb) and mean corpuscular hemoglobin concentration (MCHC) directly compromise systemic oxygen delivery and cellular respiration, presenting a clear physiological pathway to clinical fatigue.

Mechanistic pathways of cellular energy

• Oxygen delivery constraints: Hemoglobin drives systemic oxygen delivery ($DO_2$) by determining arterial oxygen content ($CaO_2$). MCHC, which typically centers around 34 g/dL, represents the density of hemoglobin within red blood cells. Below-optimal levels of these indices impair overall oxygen-carrying capacity, resulting in tissue deoxygenation and localized hypoxia under metabolic stress.
• Mitochondrial impairment: Oxygen serves as the terminal electron acceptor in the mitochondrial electron transport chain. When oxygen delivery is constrained, local oxygen tension drops below the threshold required for maximal respiration, directly limiting oxidative phosphorylation (OXPHOS) and ATP synthesis. To compensate for this energy deficit, cells shift toward anaerobic glycolysis, reducing energetic efficiency.

Clinical evidence and fatigue

• Hematological thresholds: For adult females, clinical anemia is defined as hemoglobin below 12.0 g/dL, with levels between 8.0 and 10.0 g/dL strongly associated with pronounced subjective fatigue and reduced exercise tolerance. Additionally, low MCHC indicates hypochromia, which serves as a clinical marker for early-stage iron depletion.
• Role of iron status: Iron deficiency (indicated by low ferritin) impairs hemoglobin synthesis, leading to sub-optimal red cell indices. Notably, iron deficiency is directly associated with subjective fatigue independent of anemia status. Randomized controlled trials show that correcting these sub-optimal indices through targeted iron supplementation successfully raises Hb and MCHC while significantly mitigating fatigue.

Bottom line

• Sub-optimal hemoglobin and MCHC restrict oxygen delivery to tissues, limiting mitochondrial ATP production and driving clinical fatigue; restoring these red cell indices through targeted interventions successfully relieves fatigue symptoms.